Everest Medicines Limited

Asahi Kasei Corporation aims to build on the US presence it established and the health care business growth it jumpstarted when it bought Veloxis Pharmaceuticals A/S by paying approximately $1.1bn

Calliditas Therapeutics AB 's bid to get a second asset across the regulatory finishing line – following its immunoglobulin A nephropathy (IgAN) treatment Tarpeyo – seems to have been boosted despite

The month of March will bring eight more chances for the US FDA to approve novel drugs and biologics, potentially providing a corrective to 2024’s slow start for innovative approvals. The number of us

Amid an ongoing capital crunch, Chinese drug makers pursuing in-licensing models have arrived at a commercialization crossroads. Jump-started by frontrunner Zai Lab Ltd. ’s successful introduction of